Surface Oncology, Inc. SURF
Day range unavailable
52-week range unavailable
- Market cap
- 65.08M
- Shares out
- 60.72M
- Forward P/E
- -0.79
- Beta
- 1.74
- Analysts
- Hold
- Price target
- 2.38 (+122.4%)
- Earnings date
- Nov 1, 2023
2Y -6.34 (-85.56%)
Key statistics
- Enterprise value
- 13.51M
- PEG ratio
- 0.00
- Price / book
- 0.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -28.18M
- Total cash
- 102.06M
- Total debt
- 55.46M
- Return on equity
- -80.36%
- Short % of float
- 0.78%
- 50-day average
- 0.77176
- 200-day average
- 0.84846
Analyst view
Consensus: hold
- Target (low)
- 1.00
- Target (mean)
- 2.38
- Target (high)
- 5.00
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 1, 2023
Expected Nov 1, 2023. Consensus EPS estimate -0.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 1, 2023 | Sep 1, 2023 | -0.36 | — | — | — |
| Aug 2, 2023 | Jun 1, 2023 | -0.34 | — | — | — |
| May 4, 2023 | Mar 1, 2023 | -0.37 | — | — | — |
| Mar 9, 2023 | Dec 1, 2022 | -0.27 | — | — | — |
| Nov 2, 2022 | Sep 1, 2022 | -0.46 | — | — | — |
| Aug 3, 2022 | Jun 1, 2022 | -0.44 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 20, 2023 | Wedbush | down | Outperform | Neutral |
| Jun 20, 2023 | Baird | down | Outperform | Neutral |
| Jun 20, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| May 5, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Jun 23, 2023 | Baird | main | Outperform | Outperform |
| Mar 10, 2023 | Wedbush | reit | — | Outperform |
About Surface Oncology, Inc.
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- surfaceoncology.com
News
Stocks That Hit 52-Week Lows On Friday 
Stocks That Hit 52-Week Lows On Wednesday 
Stocks That Hit 52-Week Lows On Tuesday - Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Monday 
Stocks That Hit 52-Week Lows On Thursday 
Stocks That Hit 52-Week Lows On Tuesday 
Stocks That Hit 52-Week Lows On Monday - Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Monday
Your note
Sign in to keep a note on SURF — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 31, 2020 | 0 |
| FEES JESSICA | Chief Financial Officer | Sale | Aug 2, 2022 | 111,349 |
| GOATER J JEFFREY | Director | Sale | Jul 20, 2021 | 129,222 |
| GRAYZEL DAVID S | Director | Sale | Dec 16, 2020 | 0 |
| NEW ENTERPRISE ASSOCIATES 14, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | May 19, 2020 | 0 |
| NOGELO LIISA I | Officer | Sale | Jul 20, 2021 | 53,675 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 5.08% | 3,082,959 | 2.89M | Mar 30, 2023 |
| Atlas Venture Associates IX, LLC | 4.85% | 2,945,453 | 2.76M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 3.80% | 2,309,286 | 2.16M | Mar 30, 2023 |
| ARK Investment Management, LLC | 2.33% | 1,412,077 | 1.32M | Jun 29, 2023 |
| Tang Capital Management, LLC | 2.14% | 1,300,000 | 1.22M | Mar 30, 2023 |
| DAFNA Capital Management, LLC | 1.81% | 1,100,000 | 1.03M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Genomic Revolution ETF | 9.04% | 5,488,910 | 5.14M | Mar 30, 2023 |
| Vanguard Total Stock Market Index Fund | 2.81% | 1,709,153 | 1.60M | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 0.88% | 536,790 | 502.65K | Dec 30, 2022 |
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.58% | 350,000 | 327.74K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.32% | 196,141 | 183.67K | Feb 27, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.26% | 157,500 | 147.48K | Dec 30, 2022 |